National and international guidelines increasingly emphasize the importance of biomarker testing for oncogenic driver mutations in metastatic non-small cell lung cancer (NSCLC). Recent advancements in Droplet Digital PCR (ddPCR) technology have enabled more sensitive detection and quantification of nucleic acid targets, making it a pivotal tool in oncology research. This innovative approach supports a range of applications, including biomarker characterization and molecular profiling studies, which are essential for advancing personalized medicine.
In an upcoming webinar, experts Prithwish Pal, PhD, and Surbhi Jain, PhD, will delve into the transformative role of ddPCR in clinical research and translational oncology. Dr. Pal will focus on the application of ddPCR in liquid biopsies, highlighting its capacity for highly sensitive variant detection. Dr. Jain will present analytical data from the ddPLEX EGFR/KRAS/BRAF Mutation Detection Assay Kit, showcasing its exceptional performance in detecting mutations in plasma cell-free DNA and FFPE specimens. The implications of these advancements are significant, as they could lead to improved diagnostic accuracy and treatment monitoring in NSCLC, ultimately enhancing patient outcomes.
Open the full market picture for your next decision →
